These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 33994440)

  • 21. Hepatitis B Reactivation in Patients Treated with Direct-Acting Antivirals for Hepatitis C.
    Toka B; Köksal AŞ; Dertli R; Şirin G; Fidan S; Ülger Y; Harmandar F; Yıldırım AE; Eminler AT; Asil M; Kayar Y; Bıyık M; Kuran S; Uslan MI; Hülagü S
    Dig Dis; 2022; 40(5):635-643. PubMed ID: 35108715
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Direct-acting antivirals and hepatitis B virus (HBV) reactivation in co-infected HBV/HCV kidney-transplant recipients.
    Pol S; Marion O; Vallet-Pichard A; Meritet JF; Sauné K; Alric L; Kamar N
    Transpl Infect Dis; 2018 Jun; 20(3):e12864. PubMed ID: 29512231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Co-infection with hepatitis B does not alter treatment response in chronic hepatitis C.
    Uyanikoglu A; Akyuz F; Baran B; Simsek BP; Ermis F; Demir K; Gulluoglu M; Badur S; Kaymakoglu S
    Clin Res Hepatol Gastroenterol; 2013 Nov; 37(5):485-90. PubMed ID: 23665172
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of hepatitis B virus reactivation in hepatitis B virus + hepatitis C virus-co-infected patients with compensated liver cirrhosis treated with ombitasvir, paritaprevir/r + dasabuvir + ribavirin.
    Preda CM; Popescu CP; Baicus C; Constantinescu I; Oproiu A; Voiosu T; Diculescu M; Negreanu L; Gheorghe L; Sporea I; Trifan A; Ceausu E; Proca D; Manuc M
    J Viral Hepat; 2018 Jul; 25(7):834-841. PubMed ID: 29397016
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of patients with dual hepatitis C virus and hepatitis B virus infection: resolved and unresolved issues.
    Liu CJ
    J Gastroenterol Hepatol; 2014 Jan; 29(1):26-30. PubMed ID: 24199625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virus.
    Kim YJ; Lee JW; Kim YS; Jeong SH; Kim YS; Yim HJ; Kim BH; Lee CK; Park CK; Park SH
    Korean J Hepatol; 2011 Sep; 17(3):199-205. PubMed ID: 22102386
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The course of inactive hepatitis B in hepatitis-C-coinfected patients treated with interferon and ribavirin.
    Viganò M; Aghemo A; Iavarone M; Rumi MG; Agnelli F; Lampertico P; Donato MF; Colombo M
    Antivir Ther; 2009; 14(6):789-96. PubMed ID: 19812441
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sustained HCV-RNA response and hepatitis Bs seroconversion after individualized antiviral therapy with pegylated interferon alpha plus ribavirin and active vaccination in a hepatitis C virus/hepatitis B virus-coinfected patient.
    Potthoff A; Deterding K; Trautwein C; Rifai K; Manns MP; Wedemeyer H
    Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):906-9. PubMed ID: 17873617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin.
    Potthoff A; Berg T; Wedemeyer H;
    Scand J Gastroenterol; 2009; 44(12):1487-90. PubMed ID: 19900055
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up.
    Yu ML; Lee CM; Chen CL; Chuang WL; Lu SN; Liu CH; Wu SS; Liao LY; Kuo HT; Chao YC; Tung SY; Yang SS; Kao JH; Su WW; Lin CL; Yang HC; Chen PJ; Chen DS; Liu CJ;
    Hepatology; 2013 Jun; 57(6):2135-42. PubMed ID: 23322699
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers.
    Senturk H; Tahan V; Canbakan B; Uraz S; Ulger Y; Ozaras R; Tabak F; Mert A; Ozbay G
    Neth J Med; 2008 May; 66(5):191-5. PubMed ID: 18490796
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A case of acute hepatitis B in a chronic hepatitis C patient after daclatasvir and asunaprevir combination therapy: hepatitis B virus reactivation or acute self-limited hepatitis?
    Hayashi K; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Nishimura D; Goto H; Hirooka Y
    Clin J Gastroenterol; 2016 Aug; 9(4):252-6. PubMed ID: 27329484
    [TBL] [Abstract][Full Text] [Related]  

  • 33. No evidence of hepatitis B virus reactivation in patients with resolved infection treated with direct-acting antivirals for hepatitis C in a large real-world cohort.
    Mücke VT; Mücke MM; Peiffer KH; Weiler N; Welzel TM; Sarrazin C; Zeuzem S; Berger A; Vermehren J
    Aliment Pharmacol Ther; 2017 Aug; 46(4):432-439. PubMed ID: 28627791
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatitis B virus reactivation among hepatitis C patients treated with direct-acting antiviral therapies in routine clinical practice.
    Loggi E; Gitto S; Galli S; Minichiello M; Conti F; Grandini E; Scuteri A; Vitale G; Di Donato R; Cursaro C; Furlini G; Andreone P
    J Clin Virol; 2017 Aug; 93():66-70. PubMed ID: 28654775
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interferon and ribavirin treatment results of patients with HBV-HCV co-infection cured of childhood malignancies.
    Urganci N; Gulec S; Dogan S; Nuhoglu A
    Int J Infect Dis; 2006 Nov; 10(6):453-7. PubMed ID: 17000127
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Updates on the treatment and outcomes of dual chronic hepatitis C and B virus infection.
    Liu CJ; Chen PJ
    World J Gastroenterol; 2014 Mar; 20(11):2955-61. PubMed ID: 24659886
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals.
    Belperio PS; Shahoumian TA; Mole LA; Backus LI
    Hepatology; 2017 Jul; 66(1):27-36. PubMed ID: 28240789
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful treatment of HBV, HCV, & HEV, with 12-week long use of tenofovir, sofosbuvir, daclatasvir, and ribavirin: A case report.
    Wahid B
    J Infect Public Health; 2020 Jan; 13(1):149-150. PubMed ID: 31235341
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection.
    Yeh ML; Huang CF; Huang CI; Holmes JA; Hsieh MH; Tsai YS; Liang PC; Tsai PC; Hsieh MY; Lin ZY; Chen SC; Huang JF; Dai CY; Chuang WL; Chung RT; Yu ML
    J Hepatol; 2020 Jul; 73(1):62-71. PubMed ID: 32061869
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of HCV co-infection with occult hepatitis B virus in patients undergoing IFN therapy.
    Khattab E; Chemin I; Vuillermoz I; Vieux C; Mrani S; Guillaud O; Trepo C; Zoulim F
    J Clin Virol; 2005 Jun; 33(2):150-7. PubMed ID: 15911431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.